Neuropsychological markers of mild cognitive impairment

author: Simon Brezovar, Department of Neurology, University Medical Centre Ljubljana
published: Sept. 7, 2015,   recorded: May 2015,   views: 1804


Related Open Educational Resources

Related content

Report a problem or upload files

If you have found a problem with this lecture or would like to send us extra material, articles, exercises, etc., please use our ticket system to describe your request and upload the data.
Enter your e-mail into the 'Cc' field, and we will keep you updated with your request's status.
Lecture popularity: You need to login to cast your vote.


Mild cognitive impairment (MCI) represents clinically significant cognitive decline with preserved everyday functioning. Vast amount of studies have shown that patients with MCI have increased risk for development symptoms of dementia. The probability of slowing down symptoms of dementia is closely related with an early diagnosis and intervention. Therefore, correct and reliable diagnosis of MCI plays very important role for clinicians, patients and their care-givers in making important decisions in subsequent treatment. Neuropsychological assessment aims to address question regarding level and type of cognitive decline. In the MCI literature we can find large amount of studies where neuropsychological data have been combined with other examinations (e.g. CSF, MRI, EEG). These studies have usually addressed question which combination of biomarkers are optimal in predicting individual progress to dementia. The aim of neuropsychological part of our study was (i) to find the neuropsychological measurements which are the best in predicting conversion from MCI to dementia, (ii) to separate different MCI subgroups by means of calculating robust memory and non-memory components, (iii) to combine the most predictive neuropsychological variables with other examinations and (iv) to address the question how are neuropsychological scores in MCI patients related to different modes of cognitive control. We recruited 80 participants (20 controls, 20 MCI, 20 Parkinson’s disease (PB), and 20 PB with MCI) to obtain the information about their cognitive functions.

See Also:

Download slides icon Download slides: snc2015_brezovar_cognitive_impairment_01.pdf (555.4 KB)

Help icon Streaming Video Help

Link this page

Would you like to put a link to this lecture on your homepage?
Go ahead! Copy the HTML snippet !

Write your own review or comment:

make sure you have javascript enabled or clear this field: